MX2024007319A - Proteinas de fusion que comprenden enzimas de alfa-l-iduronidasa y metodos. - Google Patents
Proteinas de fusion que comprenden enzimas de alfa-l-iduronidasa y metodos.Info
- Publication number
- MX2024007319A MX2024007319A MX2024007319A MX2024007319A MX2024007319A MX 2024007319 A MX2024007319 A MX 2024007319A MX 2024007319 A MX2024007319 A MX 2024007319A MX 2024007319 A MX2024007319 A MX 2024007319A MX 2024007319 A MX2024007319 A MX 2024007319A
- Authority
- MX
- Mexico
- Prior art keywords
- iduronidase
- alpha
- enzymes
- methods
- fusion proteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01076—L-Iduronidase (3.2.1.76)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163291283P | 2021-12-17 | 2021-12-17 | |
| PCT/US2022/053196 WO2023114485A1 (en) | 2021-12-17 | 2022-12-16 | Fusion proteins comprising alpha-l-iduronidase enzymes and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024007319A true MX2024007319A (es) | 2024-07-22 |
Family
ID=85175822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024007319A MX2024007319A (es) | 2021-12-17 | 2022-12-16 | Proteinas de fusion que comprenden enzimas de alfa-l-iduronidasa y metodos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250136963A1 (enExample) |
| EP (1) | EP4448746A1 (enExample) |
| JP (1) | JP2024546129A (enExample) |
| KR (1) | KR20240119118A (enExample) |
| CN (1) | CN118401660A (enExample) |
| AR (1) | AR128003A1 (enExample) |
| AU (1) | AU2022415476A1 (enExample) |
| CA (1) | CA3241240A1 (enExample) |
| IL (1) | IL313553A (enExample) |
| MX (1) | MX2024007319A (enExample) |
| TW (1) | TW202340459A (enExample) |
| WO (1) | WO2023114485A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020252554B2 (en) | 2019-04-03 | 2026-05-28 | Denali Therapeutics Inc. | Formulations of protein molecules comprising iduronate 2-sulfatase |
| TW202542190A (zh) * | 2023-12-20 | 2025-11-01 | 美商戴納立製藥公司 | 包含酸性α—葡萄糖苷酶之融合蛋白及其方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017534640A (ja) * | 2014-11-10 | 2017-11-24 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルファ−ｌ−イズロニダーゼ、イズロン酸−２−スルファターゼおよびアルファガラクトシダーゼａの治療用組成物ならびにそれらの使用方法 |
| CA2990785C (en) * | 2015-06-24 | 2024-11-12 | Jcr Pharmaceuticals Co., Ltd. | ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER |
| EP4628586A3 (en) | 2017-02-17 | 2026-01-14 | Denali Therapeutics Inc. | Transferrin receptor transgenic models |
| BR112020005271A2 (pt) | 2017-10-02 | 2020-09-15 | Denali Therapeutics Inc. | proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica |
| WO2019246071A1 (en) * | 2018-06-18 | 2019-12-26 | Denali Therapeutics Inc. | Fusion proteins comprising progranulin |
| WO2021158986A1 (en) * | 2020-02-07 | 2021-08-12 | Denali Therapeutics Inc. | Methods for the treatment of hunter syndrome |
-
2022
- 2022-12-16 AR ARP220103478A patent/AR128003A1/es unknown
- 2022-12-16 EP EP22854477.1A patent/EP4448746A1/en active Pending
- 2022-12-16 WO PCT/US2022/053196 patent/WO2023114485A1/en not_active Ceased
- 2022-12-16 CN CN202280083088.0A patent/CN118401660A/zh active Pending
- 2022-12-16 IL IL313553A patent/IL313553A/en unknown
- 2022-12-16 JP JP2024534711A patent/JP2024546129A/ja active Pending
- 2022-12-16 AU AU2022415476A patent/AU2022415476A1/en active Pending
- 2022-12-16 MX MX2024007319A patent/MX2024007319A/es unknown
- 2022-12-16 CA CA3241240A patent/CA3241240A1/en active Pending
- 2022-12-16 US US18/719,958 patent/US20250136963A1/en active Pending
- 2022-12-16 KR KR1020247022697A patent/KR20240119118A/ko active Pending
- 2022-12-16 TW TW111148472A patent/TW202340459A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202340459A (zh) | 2023-10-16 |
| CA3241240A1 (en) | 2023-06-22 |
| IL313553A (en) | 2024-08-01 |
| EP4448746A1 (en) | 2024-10-23 |
| WO2023114485A1 (en) | 2023-06-22 |
| CN118401660A (zh) | 2024-07-26 |
| KR20240119118A (ko) | 2024-08-06 |
| AR128003A1 (es) | 2024-03-20 |
| US20250136963A1 (en) | 2025-05-01 |
| JP2024546129A (ja) | 2024-12-17 |
| AU2022415476A1 (en) | 2024-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020550510A1 (en) | Fusion proteins comprising enzyme replacement therapy enzymes | |
| CR20230178A (es) | Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas | |
| MX2020007024A (es) | Sialidasas humanas recombinantes, proteinas de fusion de sialidasa y metodos para usar las mismas. | |
| NZ743008A (en) | Compositions and methods for internalizing enzymes | |
| UY40421A (es) | Formulación que comprende una enzima que cataliza la producción de óxido nítrico | |
| MY198804A (en) | Compositions and methods for internalizing enzymes | |
| MX2023001595A (es) | Proteinas de fusion que comprenden proteinas de leche y composiciones de las mismas. | |
| MX2023000243A (es) | Sialidasas recombinantes con sensibilidad reducida a la proteasa, proteinas de fusion de sialidasa y metodos para utilizarlas. | |
| EA201892561A1 (ru) | Гибридные белки gdf15 и их применение | |
| WO2021003469A3 (en) | Recombinant human sialidases, sialidase fusion proteins, and methods of using the same | |
| MX2020006635A (es) | Proteína de fusión enzimática terapéutica que tiene una nueva estructura y uso de la misma. | |
| EP4667565A3 (en) | Methods and compositions for the treatment of fabry disease | |
| ZA202402034B (en) | Caix targeting il-12 fusion proteins and methods of use thereof | |
| PH12022552935A1 (en) | Stabilized coronavirus spike protein fusion proteins | |
| EP4011906A3 (en) | Lactase enzymes with improved properties | |
| WO2021248087A3 (en) | Enzymes and regulatory proteins in tryptamine metabolism | |
| MX2025005078A (es) | Composiciones que contienen enzimas que escinden anticuerpos y metodos de uso de las mismas. | |
| Bachran et al. | Anthrax toxin-mediated delivery of the Pseudomonas exotoxin A enzymatic domain to the cytosol of tumor cells via cleavable ubiquitin fusions | |
| MX2024011115A (es) | Enzimas escualeno-hopeno-ciclasa (shc) y variantes de enzimas. | |
| MX2022004311A (es) | Estirpes celulares de mamiferos con deficiencia de lipasa/esterasa modificadas geneticamente de manera recombinante. | |
| MX2023009737A (es) | Proteínas de fusion y constructos de acidos nucleicos. | |
| WO2023159136A3 (en) | Epitope engineering of cell-surface receptors | |
| IL313553A (en) | Fusion proteins containing alpha-L-iduronidase enzymes and methods | |
| MX2019009063A (es) | Proteinas de fusion del factor ix y procedimientos de preparacion y utilizacion de las mismas. | |
| ZA202308985B (en) | Constructs and methods for increased expression of polypeptides |